Daily Dose of PRL-8-53: 0.01-4mg/kg of bodyweight
PRL-8-53 is a nootropic research compound that, much like other nootropics, can greatly improve cognitive function and especially memory. PRL-8-53 is a synthetic nootropic supplement, meaning it was created in a lab, by Dr. Nikolaus Hansl. It got its name from Hansl’s then company Pacific Research Labs, where most of the research had been done. It has been known and studied for its ability to greatly increase a person’s short term memory.
One human study was done where participants took a placebo following a memory test, then took the memory test again but this time after supplementation. The memory test consisted of twelve monosyllabic words in a particular order. It was taken three times, immediately after supplementation, one day after supplementation, and four days after supplementation. There were minor benefits towards people who were able to remember 8 words after taking the placebo. However, participants who had poor short term memory benefited greatly from taking the supplements and their score on the memory test doubled. These participants with poor short term memory also experienced additional benefits that people with strong short term memory did not. An example of these additional benefits is the improvement of working memory, or remembering details until it can cement into long term memory.
Although there have not been any reports on serious side effects of taking PRL-8-53, very few studies have been conducted on it and it is not advised at this time to take it. No side effects were recorded in human trials but when mice and rats were given large doses, they experienced reduced motor activity. In the studies, individuals were given 5mg of PRL-8_53 a day. The patent information for PRL 8-53 suggests a range of 0.01-4mg/kg of body weight however, as that is a very large range, the ideal range is 0.05-1.2 mg/kg.
- Hansl NR, Mead BT. PRL-8-53: enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent. Psychopharmacology (Berl). 1978 Apr 11;56(3):249-53. PMID: 418433.